iProtics is developing a novel drug to treat blood cancers and autoimmune diseases more effectively and with fewer side effects than current treatments. Existing drugs inhibit both immunoproteasomes and constitutive proteasomes, causing severe side effects by damaging healthy cells. iProtics has created a first-in-class drug that selectively inhibits only immunoproteasomes, which are primarily found in cancer cells and overactive immune cells. This targeted approach kills harmful cells while sparing healthy ones. The drug could improve treatment for millions of patients with multiple myeloma, leukemia, lupus, and other diseases, potentially becoming a first-line therapy and reducing healthcare costs. Within the BB programme, iProtics will conduct key preclinical studies to validate their lead compound’s efficacy and safety. This includes in vivo animal studies for blood cancers and autoimmune diseases, toxicology and pharmacology experiments, scaling up drug manufacturing, and preparing regulatory documentation to advance towards clinical trials.
The company’s goal is to develop a breakthrough therapy that transforms treatment for patients suffering from these serious diseases. iProtics is excited to leverage the BB
programme’s support to accelerate progress towards the clinic and ultimately improve patients’ lives through their innovative approach to immunoproteasome inhibition.
